Harrison Barnes (Sacramento Kings) with a 2-pointer vs the Utah Jazz, 04/10/2021
Harrison Barnes (Sacramento Kings) with a 2-pointer vs the Utah Jazz, 04/10/2021
BEVERLY, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, is pleased to announce the hiring of four additional sales representatives, including three for the veterinary market and one for the contract drug manufacturing market. Dr. Jack Regan, LexaGene’s CEO and Founder states, “We are excited to have recruited very talented and experienced sales representatives from some of the biggest names in veterinary healthcare. Our new sales representatives have universally expressed optimism about selling LexaGene’s technology into veterinary hospitals, and the same is true for our sales representative targeting contract drug manufacturing organizations. Our rapidly growing sales team is now undergoing LexaGene specific training and will soon be offering incentives for early adopters so we can quickly expand our installation base.” Dr. Regan continues, “We are focusing on the veterinary market as we see it as a largely untapped market. There are 77M dogs and 58M cats in the United States,1 and many pet owners spare no expense on caring for their animal companions. The overall size of the veterinary diagnostics market is expected to soon reach $4B and is growing at a compound annual growth rate “CAGR” of 8.8%.2 Currently, there are 18,600 private practice veterinary clinics that see enough animals per day to be target customers for LexaGene.3,4” Feedback from key opinion leaders has boosted the Company’s confidence that the MiQLab™ system will become a powerful tool for veterinarians interested in rapid in-clinic diagnostics to improve patient care. The MiQLab represents a change in business model for veterinarians who currently rely on reference laboratories for infectious disease testing. Instead of shipping samples out and waiting days for results, the MiQLab generates results, inside the clinic, soon after the patient sample has been collected. This drastic improvement in time-to-result, particularly when antibiotic resistant superbugs are detected, is expected to improve prescription practices and lead to better patient outcomes. Jeff Mitchell, LexaGene’s CFO, adds, “We are anticipating strong demand in veterinary diagnostics and have strategically hired additional sales managers to more effectively cover the United States. Although new technology adoption does take time, we are very optimistic that a significant percentage of the targeted practices will soon become LexaGene customers. While searching for additional sales managers, we were excited and gratified to see the amount of interest from many seasoned sales professionals working for the largest animal health companies in the United States.” From a very talented pool of candidates, the Company has hired the following sales managers for veterinary diagnostics sales and open-access sales: Julie Griggs is LexaGene’s West Regional Sales Manager. She has 18 years of experience in companion animal health and comes to LexaGene from Antech Diagnostics. Previously, she worked for Covetrus, Zoetis, Banfield, Village Animal Clinic, and Sunburst Animal Clinic. Julie is a Certified Veterinary Technician. Kara Alkire is LexaGene’s Southeast Regional Sales Manager. She has 15 years of sales experience in companion animal health and comes to LexaGene from Bayer Animal Health / Elanco. Previously, she worked at Heska selling companion animal health products. Kara has a Bachelor of Science in Biology with a Minor in Chemistry from the College of Charleston, SC. Whitney Fernandes is LexaGene’s Northeast Regional Sales Manager. She has 8 years of sales experience in companion animal health and equine. She comes to LexaGene from American Regent Animal Health and previously worked at Smartpak Equine. Whitney is a certified pharmacy technician and has a Bachelor of Science in Business Management from the University of Massachusetts. Chris Bartlett is LexaGene’s Open-Access Sales Manager. He has 20 years of experience specializing in the sale of capital equipment technologies for laboratory, diagnostic, and single use bioprocessing applications. Chris comes to LexaGene from Refine Technology and has a Bachelor of Science degree in Microbiology from North Carolina State University. These highly talented sales managers join Sarah Mumbower, LexaGene’s Midwest Regional Sales Manager. Sarah has 5 years’ experience in companion animal health and came to LexaGene in 2020 from IDEXX. She is a Certified Veterinary Technician. In addition, LexaGene is announcing that on May 11, 2021, the board of directors approved inducement grants in accordance with the Company’s Omnibus Incentive Plan (the “Plan”) for independent, non-executive directors totaling 396,000 restricted share units (“RSUs”) and 396,000 share options (“Options”). The sum covers an initial grant for LexaGene’s newest board member who joined in February, as well as annual grants for the other three independent non-executive directors. Each Option is exercisable into one common share of the Company (“Share”) at a price of CAD$0.66 per Share, for a period of ten years from the date of grant. The CAD$0.66 per share was 120% above the close price of the Company’s stock on the TSX Venture Exchange on May 10, 2021. The Options vest 10% on the grant date, and 15% every six months thereafter with an expiry date of May 11, 2031. The RSUs start vesting on May 11, 2023, in equal 10% increments on the 11th day of each month thereafter expiring on February 11, 2024. To be added to the LexaGene email list, please subscribe on the Company website. On Behalf of the Board of DirectorsDr. Jack ReganChief Executive Officer & Chairman About LexaGene Holdings Inc.LexaGene is a molecular diagnostics company that develops molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for on-site rapid testing in veterinary diagnostics, food safety and for use in open-access markets such as clinical research, agricultural testing and biodefense. End-users simply need to collect a sample, load it onto the instrument with a sample preparation cartridge, enter sample ID and press ‘go’. The MiQLab™ system delivers excellent sensitivity, specificity, and breadth of detection and can return results in approximately two hours. The unique open-access feature is designed for custom testing so that end-users can load their own real-time PCR assays onto the instrument to target any genetic target of interest. The TSX Venture Exchange Inc. has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors -- including the availability of funds, the results of financing efforts, the success of technology development efforts, the cost to procure critical parts, performance of the instrument, market acceptance of the technology, regulatory acceptance, and licensing issues -- that could cause actual results to differ materially from the Company's expectations as disclosed in the Company's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ________________________ 1 https://www.avma.org/resources-tools/reports-statistics/us-pet-ownership-statistics2 https://www.marketsandmarkets.com/Market-Reports/veterinary-diagnostics-market-26017452.html?gclid=EAIaIQobChMI2duon7Oy7AIVohx9Ch0vAAHoEAAYASAAEgLbwPD_BwE3 U.S. Department of Labor, Census Bureau 20184 https://www.avma.org/sites/default/files/resources/2018-econ-rpt3-veterinary-services.pdf
Diversified Technologies, Inc. has introduced a compact and customizable high voltage pulse generator for production and research applications including plasma processes and ion implantation.
Reduces borrowing costs with one of the industry’s leading annual interest rates of 9.75%Credit agreement is non-dilutiveImproves liquidity and operational flexibilitySupports the Company’s continued strategic growth plans CHICAGO, May 11, 2021 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (CSE: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced it has entered into an Amended and Restated Credit Agreement (the “Restated Credit Agreement”) for a senior secured term loan of US$130 million. The Restated Credit Agreement has a maturity date of May 30, 2023, and provides for additional, non-dilutive funding of US$100 million, with an annual interest rate of 9.75% for the incremental amount. Chicago Atlantic Advisers, LLC (“Chicago Atlantic”) will act as the administrative agent and collateral agent. Closing on the foregoing transaction is subject to customary conditions, contingencies and approvals. “This upsized credit facility was strategically planned to provide additional coverage of recently announced M&A activity, to enhance our overall financial position, and create flexibility for us to pursue opportunities that could drive further growth and margin expansion,” said George Archos, Verano Co-Founder and CEO. “We very much appreciate the support of Chicago Atlantic, and the improved terms of the new facility. Being able to secure one of industry’s leading rates signals the growth in acceptance of the cannabis industry as it continues to evolve and mature.” In making the announcement, John Mazarakis, Partner of Chicago Atlantic, noted, "We are excited to see Verano execute on its growth plan and we are looking forward to expanding our partnership. The terms of the upsized loan reflect Verano’s impressive operating performance, which resulted in this credit facility carrying one of the lowest cost of capital to-date in the industry. Verano is a clear leader in the cannabis space, and the company's consistent focus on profitable growth is what attracted us to this opportunity." About VeranoVerano Holdings Corp. is a leading, vertically-integrated, multi-state cannabis operator in the U.S., devoted to the ongoing improvement of communal wellness by providing responsible access to regulated cannabis products. With a mission to address vital health and wellness needs, Verano produces a comprehensive suite of premium, innovative cannabis products sold under its trusted portfolio of consumer brands: Verano, Avexia, Encore, and MÜV™. The company’s portfolio encompasses 14 U.S. States, with active operations in 11, which includes nine production facilities comprising approximately 770,000 square feet of cultivation. Verano designs, builds, and operates dispensaries under retail brands Zen Leaf™ and MÜV™, delivering a superior cannabis shopping experience in both medical and adult-use markets. Learn more at www.verano.com About Chicago Atlantic Advisers / Green Ivy CapitalChicago Atlantic Advisers, LLC is an asset management firm specializing in direct lending and opportunistic private credit investing. Founded in 2018 by Tony Cappell, John Mazarakis, and Andreas Bodmeier, the firm seeks to capitalize on North American investment opportunities that are time-sensitive, complex, or in dislocated markets, where risk is fundamentally mispriced. Through its affiliate Green Ivy Capital, LLC, the firm manages a diversified portfolio of credit investments in the cannabis space and is actively investing across the value chain. Forward Looking StatementsThis press release may contain certain "forward-looking information" within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company's control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or may contain statements that certain actions, events or results "may", "could", "would", "might" or "will be taken", "will continue", "will occur" or "will be achieved". Forward-looking information and forward-looking statements may include, but are not limited to statements or information with respect to the Company’s position in the marketplace, the Company’s strategic growth plans, and delivery of shareholder value. Forward-looking information and statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking information and statements herein, including, without limitation, the risk factors discussed in the Company's filings on SEDAR at www.sedar.com. Any forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking information or forward-looking statements that are contained or referenced herein, except as may be required in accordance with applicable securities laws. All subsequent written and oral forward- looking information and statements attributable to the Company or persons acting on its behalf is expressly qualified in its entirety by this notice regarding forward-looking information and statements. *** Contacts: InvestorsVerano HoldingsAaron MilesHead of Investor Relationsaaron@verano.holdings MediaVerano HoldingsDavid SpreckmanVP, Marketing & Communications email@example.com
Ferro Corporation (NYSE: FOE) (the Company), a leading global supplier of technology-based functional coatings and color solutions, today announced it has entered into a definitive agreement to be acquired by Prince International Corporation, a portfolio company of American Securities LLC, in an all-cash transaction valued at approximately $2.1 billion, or 12.4 times TTM Adjusted EBITDA as of March 31, 2021, including the assumption of debt, net of cash. Under the terms of the agreement, which has been unanimously approved by the Ferro Corporation Board of Directors, Prince will acquire all of the outstanding common stock of Ferro for $22.00 per share in cash. The purchase price represents a 25.1% premium to the closing stock price on May 10, 2021 of $17.58 per share and a 33.8% premium to the 90-day volume-weighted average price.
Hewlett Packard Enterprise to Present Live Audio Webcast of Second Quarter Earnings Conference Call
Daikin Applied today announced updates to its Rebel Applied™ packaged rooftop HVAC system, known for its leading airflow and efficiency ratings, and compact footprint. Rebel Applied now comes with inverter scroll compressors, precision temperature and humidity control, and adaptive refrigeration technology, expanding its ability to provide unmatched energy efficiency and enhanced indoor comfort.
The "Tiger Nuts Milk Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020-2030" report has been added to ResearchAndMarkets.com's offering.
TORONTO, May 11, 2021 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, is pleased to announce it will release first quarter financial results for the three month period ended March 31, 2021 before markets open on Monday, May 17, 2021. MediPharm Labs executive management team will also host a conference call and audio webcast on Monday, May 17, 2021, at 8:30 a.m. eastern time to discuss the Company’s financial results and outlook. Audio Conference Call Dial In Details: Toll-free number: +1-833-502-0471 / International number: +1-236-714-2179 / Conference ID: 5847315 Participants are asked to dial in approximately 15 minutes before the start of the call. Audio Webcast: An audio webcast will be available in the Events section of the MediPharm Labs’ Investor Relations website https://ir.medipharmlabs.com/news-events or by visiting the following link here. For those who are unable to participate on the live conference call and webcast, a replay will be available approximately one hour after completion of the call. A replay of the audio webcast will be available after the call has ended until May 24, 2021 11:59 p.m. eastern time. Within North America dial +1-800-585-8367 or International dial +1-416-621-4642 outside North America using Conference ID: 5847315. About MediPharm Labs Corp. Founded in 2015, MediPharm Labs specializes in the production of purified, pharmaceutical-quality cannabis oil and concentrates and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms. MediPharm Labs has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities with five primary extraction lines for delivery of pure, trusted and precision-dosed cannabis products for its customers. Through its wholesale and white label platforms, MediPharm Labs formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. As a global leader, MediPharm Labs has completed commercial exports to Australia and has fully commercialized its Australian extraction facility. MediPharm Labs Australia was established in 2017. For further information, please contact: Laura Lepore, VP, Investor Relations Telephone: 705-719-7425 ext 1525Email: firstname.lastname@example.orgWebsite: www.medipharmlabs.com CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION: This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of MediPharm Labs to obtain adequate financing; the delay or failure to receive regulatory approvals; and other factors discussed in MediPharm Labs’ filings, available on the SEDAR website at www.sedar.com. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm Labs assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.
The "Diethyl Malonate Global Market Insights 2020, Analysis and Forecast to 2025, by Manufacturers, Regions, Technology, Application" report has been added to ResearchAndMarkets.com's offering.
Dublin, May 11, 2021 (GLOBE NEWSWIRE) -- The "Global Gaming Almanac 2020-2021 Edition" report has been added to ResearchAndMarkets.com's offering. From a synopsis of each jurisdiction's gaming activities to details on the participating properties and property owners, the Global Gaming Almanac provides a complete and well-organized overview of the gambling market in every country outside the U.S. and Canada. The Almanac describes each segment of the gaming industry including casino and card room gaming, race wagering, sports betting, commercial bingo, lotteries, charitable gaming, and online gaming. Annual financial statistics are provided in charts and tables along with the historic and current regulatory environment in each jurisdiction, an overview of pending legislation, and major trends. Counts and distribution of gaming properties, devices and tables are given along with profiles of properties, owners and regulatory agencies. The Almanac will help you gather international market data to support your business plan, analyze local and foreign competitors, and monitor global trends. Complete Overview of Gambling Worldwide Covers every world gaming jurisdiction with market summaries, financial data, statistics and profiles of properties, owners and regulators.Provides market, financial, legal, and regulatory information about land-based and online gambling in 280+ regions and jurisdictions around the globe.Will help you gather world market data to support your business plan, analyze local and foreign competitors, and monitor global trends. Key Features Coverage of nearly 300 international gaming jurisdictionsGaming property countsDevice and table counts and distribution7,000 international property profilesOver 900 property owner profiles700 regulatory agencies2015-2018 gaming revenue data by gaming type per country (available for some jurisdictions)2015-2018 year-over-year gaming revenue growth (available for some jurisdictions)Annual taxes collected from gaming activities (available for some jurisdictions)Financial data provided in local currencies and in U.S. Dollars Online Subscription The Global Gaming Almanac Online Subscription additionally contains: Global gaming interactive analysis tool with location and statistical data for all gaming properties outside the U.S. and Canada. Use the analyzer tool for custom gaming property marketplace analysis by geographic area and by type of gaming facility.Interactive global gaming property maps displaying the locations of every gaming property outside the U.S. and Canada.More than 2,100 annual reports covering international (non-U.S. and Canadian) gaming businesses that publish their financial results.Global regulatory agency and commission directory with contact data for 700 regulatory agencies and commissions around the world (outside the US and Canada) with website and e-mail addresses, agency or commission contact names and titles.Online access to the current printed Almanac and prior ten editions of the Almanac in searchable electronic format Key Topics Covered: 1. Preface 2. Overview of Gaming Worldwide 3. Gaming in Africa 4. Gaming in Asia and the Middle East 5. Gaming in the Caribbean 6. Gaming in Central and South America 7. Gaming in Europe 8. Gaming in North America 9. Gaming in Oceania 10. Gaming on Cruise Ships 11. Gaming Property Owners 12. Gaming Properties Ranked by Size Gaming MachinesTable GamesPoker TablesBingo SeatsGaming PositionsHotel Rooms 13. Gaming Properties Grouped by Property Type PlannedUnder ConstructionRacinosDog TracksHorse TracksCasino CruisesCruise Ships 14. Appendix A: Assumptions and Methodology For more information about this report visit https://www.researchandmarkets.com/r/amwsdd About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
UK, US and Asian markets fall by around 2% amid worries that inflation is set to pick up.
The euro's gains were also bolstered by widespread dollar weakness as investors waited for comments on U.S. policymaker thinking ahead of inflation data on Wednesday. Appearances later on Tuesday from U.S. Federal Reserve members John Williams, at 1430 GMT, and Lael Brainard, at 1600 GMT, will be parsed for clues as to central bank thinking. A disappointing employment report last week triggered a widespread selloff in the greenback and though surging commodity prices have raised concerns of higher inflation in the coming months, markets believe the Fed will remain on hold.
Tennessee offensive coordinator Alex Golesh went from Moscow, Russia, to coaching in America's most powerful college football conference.
The Birmingham-born actor played a security guard in the 1999 rom com starring Hugh Grant and Julia Roberts,
The "Reconstruction Meshes (General Surgery) - Global Market Analysis and Forecast Model (COVID-19 Market Impact)" report has been added to ResearchAndMarkets.com's offering.
Amid outcry, NBC says it will not air Golden Globes in 2022; Gloria Estefan, Thalia, Anitta perform at Latin Grammy tribute to women in music; Broadway theaters set to reopen, full capacity from September. (May 11)
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Nova Scotia, May 11, 2021 (GLOBE NEWSWIRE) -- NOVA LEAP HEALTH CORP. (TSXV: NLH) (“Nova Leap” or “the Company”), a home health care organization ranked #2 on the 2020 Report on Business ranking of Canada’s Top Growing Companies, is pleased to announce that Chris Dobbin, President & CEO of Nova Leap, will present at the Q2 Virtual Investor Summit event to be held May 17-18, 2021. About the Q2 Virtual Summer Summit The Investor Summit is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors. The Q2 Investor Summit will take place virtually, featuring 100 companies and over 300 institutional and retail investors. Mr. Chris Dobbin, President & CEO of Nova Leap, will be presenting at the event by way of webcast on Monday, May 17, 2021 at 11:00 AM Eastern Time / (8:00 AM Pacific Time). The unique link allowing access to the Company’s webcast is: https://zoom.us/webinar/register/WN_5NGZgUvyTYS7xgnHUK5EWg About Nova Leap Nova Leap is an acquisitive home health care services company operating in one of the fastest-growing industries in the U.S. & Canada. The Company performs a vital role within the continuum of care with an individual and family centered focus, particularly those requiring dementia care. Nova Leap achieved the #2 ranking on the 2020 Report on Business ranking of Canada’s Top Growing Companies and the #10 Ranking in the 2019 TSX Venture 50™ in the Clean Technology & Life Sciences sector. The Company is geographically diversified with operations in 7 different U.S. states within the New England, South-Central and Midwest regions as well as Nova Scotia, Canada. FORWARD LOOKING INFORMATION: Certain information in this press release may contain forward-looking statements, such as statements regarding future expansions and cost savings, the Company’s expected annualized recurring revenue run rate and plans regarding future acquisitions and financings. This information is based on current expectations and assumptions, including assumptions concerning general economic and market conditions, availability of working capital necessary for conducting Nova Leap’s operations, and Nova Leap’s ability to integrate its acquired businesses and maintain previously achieved service hour and revenue levels, that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. Risks that could cause results to differ from those stated in the forward-looking statements in this release include the impact of the COVID-19 pandemic or any recurrence, including government regulations or voluntary measures limiting the Company’s ability to provide care to clients (such as shelter-in-place orders, isolation or quarantine orders, distancing requirements, or closures or restricted access procedures at facilities where clients reside), increased costs associated with personal protective equipment and sanitization supplies, staff and supply shortages; regulatory changes affecting the home care industry, other unexpected increases in operating costs and competition from other service providers. All forward-looking statements, including any financial outlook or future-oriented financial information, contained in this press release are made as of the date of this release and included for the purpose of providing information about management's current expectations and plans relating to the future. The Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements unless and until required by securities laws applicable to the Company. Additional information identifying risks and uncertainties is contained in the Company's filings with the Canadian securities regulators, which filings are available at www.sedar.com. CAUTIONARY STATEMENT: Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. CONTACT: For further information: Chris Dobbin, CPA, CA Director, President and CEO Nova Leap Health Corp. T: 902 401 9480 F: 902 482 5177 E: firstname.lastname@example.org
Moderna has emerged as a strong competitor after getting authorization for a coronavirus vaccine. But Moderna stock remains on a wild ride. Is Moderna stock a buy now?
In January, a man in his 60s with heart disease and diabetes went to a South Dakota hospital with a cough and fever, worried he had COVID. A nurse swabbed the inside of his nose, and the sample went into a small device resembling an inkjet-printer cartridge, which was then placed into a machine about the size of a printer. This so-called quad test, now available at thousands of hospitals and clinics around the country, could detect not only the coronavirus, but two types of influenza and the respiratory syncytial virus, or RSV. A little more than a half-hour later, Dr. Blake Gustafson had the patient’s result: He had the flu. “I remember giving myself a fist bump like, ‘Yes! It’s not COVID. It’s the flu,’” said Gustafson, chief of emergency medicine of the Sanford USD Medical Center in Sioux Falls, South Dakota. He relayed the news to the patient and his wife, happily adding that there was a treatment he could offer right away, Tamiflu. “The relief in their eyes above their masks was very satisfying,” Gustafson said. Sign up for The Morning newsletter from the New York Times The patient’s situation was somewhat unusual this past winter given that the United States, like many other countries, witnessed a shocking absence of a flu season. But as the country begins to reopen, doctors say that flu and other pathogens might make a comeback this autumn. What’s more, even as a growing number of people get vaccinated against COVID, there are still some 40,000 new infections every day in the United States, and a significant number of people who may be resistant to taking the vaccines. The Sanford Health system, which includes 46 hospitals and 1,400 physicians in South Dakota, carries out 600 to 800 tests for the coronavirus a day in its clinics using antigen tests, which detect proteins made by the virus. But according to Rochelle Odenbrett, the senior executive director of laboratories, the organization is now in the process of replacing all of those tests with the quad tests used in its emergency settings. Unlike the antigen tests, the quad test looks for a virus’s genetic material using a polymerase chain reaction, or PCR for short. The PCR-based method is far more accurate than the antigen approach, Odenbrett says. She notes that PCR sequencing of patient samples used to be more cumbersome and relied on multistep procedures across different laboratory rooms. “It’s just amazing how the technology has evolved,” she said. The quad test used by the Sanford system is made by the California-based company Cepheid, which received emergency authorization from the Food and Drug Administration in late September. Although last year’s flu season was nonexistent, Dr. Geoffrey Baird of the University of Washington in Seattle said that a confluence of factors might precipitate its return in the fall: children returning to school buildings, declining use of masks and perhaps a lack of recent immune system exposure to the flu. If more people get sick in the fall, he added, they will want to know if it is flu or the coronavirus. “We in the laboratory are preparing for another big boom in testing,” said Baird, whose team has run more than 2 million coronavirus tests since the beginning of the pandemic. “Even if people are vaccinated, they’re going to wonder, ‘Am I the breakthrough case?’ ” In addition to Cepheid, other companies have developed tests that look for influenza and the coronavirus at the same time, including Roche, which has received emergency use authorization for a test that looks for the coronavirus, influenza A and influenza B at once. In recent years various hospitals have developed in-house versions of these combination tests as well, some of which look for more than a dozen different respiratory pathogens simultaneously using PCR technology. Those “multiplex” tests are especially helpful in diagnosing illnesses in people with weak immune systems because they allow doctors to swiftly discern what pathogen is making a person sick before it is too late to start the right treatments. A French company, bioMérieux, sells a PCR test that looks for the coronavirus as well as 21 other viruses and bacteria simultaneously. And Roche recently bought a company that sells a machine that can screen for more than 20 pathogens in one go. Testing for multiple pathogens does not always lead to a simple treatment, however. Co-infections, in which a person is infected with multiple viruses simultaneously, are more common than doctors expected, and sometimes the multiplex tests might detect a viral infection but miss a bacterial one, said Dr. Daniel Griffin, chief of infectious diseases at ProHealth New York. A patient could carry the influenza virus but also test positive for a bacterium such as pneumococcus, for example. “We initially thought that every time we identified a virus, we would just be able to stop all antibiotics and just treat the virus if effective antiviral therapy was available,” Griffin said. “We now know that we often need to continue antibiotics,” he explained, because sometimes the multiplex tests are not sensitive enough to rule out a bacterial culprit. Doctors and test developers are still grappling with how many pathogens to test patients for in different settings. “A burning question at every company is what panel is best — is it one, two, four, 20?” said Dr. Mark Miller, chief medical officer at bioMérieux. Relatively young and healthy adults might just need a quad test to know if they should start on Tamiflu for influenza, for example, but patients with underlying chronic diseases who are very sick might benefit from receiving the test for 22 different pathogens so that doctors can decide whether they need to be admitted to a hospital. Before the pandemic, people were not always as curious to know the exact pathogen causing respiratory symptoms, according to Dr. Alexandra Valsamakis, head of clinical development and medical affairs at Roche Diagnostics Solutions. “I think there was always this perception of ‘Oh, whatever it is, it’s not going to kill us,’ ” Valsamakis said. But the terrible toll of COVID-19 has changed that. “There’s this need to actually know what’s there, more than there ever was before.” This article originally appeared in The New York Times. © 2021 The New York Times Company
Lifesprk, leader in whole person senior services, and Tealwood Senior Living, leaders in senior living management, have partnered to bring 35 senior living properties across multiple states under Lifesprk Senior Living.